Minerval
Sourceunknownno stored text

Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation

Author not recordedDate not recordedOriginal︎ ↗Archived copy

Claims2
ExaminationsNone
TextNot stored
VersionsOne known
CopiesNone recorded
CorrectionsNone recorded
Facts checked Nov 9, 2026
ReachNo copies recorded
StructureIn 2 claims' maps0 sources downstream across 2 claims
EvidenceNot yet read
ReviewsNot reviewed

Examinations

None recorded. An examination is commissioned by a claim’s Steward for what its claim rests on; a review of the document for its own sake is asked for as a request bearing on it.

Text

No stored copy. Only the passages claims quote are recorded.

As quoted

While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP) respectively, this did not translate into major adverse cardiovascular events (MACE) risk reduction versus placebo in people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammation (hazard ratio, 0.99; 95% confidence interval, 0.88 to 1.11).

At least some anti-inflammatory therapies reduce cardiovascular events independently of lipid loweringSupportedmentions

Not yet read by this claim’s Steward.

As quoted

While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP) respectively, this did not translate into major adverse cardiovascular events (MACE) risk reduction versus placebo in people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and inflammation (hazard ratio, 0.99; 95% confidence interval, 0.88 to 1.11)

The IL-6 inhibitor ziltivekimab did not reduce cardiovascular events in the ZEUS trialVerified

Not yet read by this claim’s Steward.

Lineage across 2 claims

Draws on · none recorded
This source
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and infl…
in 2 claims' maps
Drawn on by · none recorded

Record

Kind
unknown
Authors
Not recorded
Publisher
Not recorded
Published
Not recorded
DOI
None
Link
https://www.globenewswire.com/news-release/2026/07/31/3336733/0/en/novo-nordisk-provides-update-on-the-zeus-phase-3-trial-in-people-with-ascvd-ckd-and-inflammation.html
Archived copy
https://web.archive.org/web/20260823021110/https://www.globenewswire.com/news-release/2026/07/31/3336733/0/en/novo-nordisk-provides-update-on-the-zeus-phase-3-trial-in-people-with-ascvd-ckd-and-inflammation.html
Stored text
None; quoted passages only
Claims extracted
Not recorded
Versions
One known
Copies
None recorded
Corrections
None recorded
Facts checked
Nov 9, 2026

History 2

  1. Nov 9, 2026FactsFacts fetcher · Facts looked up
  2. Aug 7, 2026Entered the graphEntered the graph; no copy stored